objeCtives: Marfan syndrome is a rare systemic connective tissue disorder caused by mutations in the gene encoding fibrillin-1 (FBN1). Marfan Syndrome has an estimated prevalence of 1 in 5,000-10,000. Disease manifestations include, but are not limited to, cardiovascular (CV) and pulmonary disorders. Among Marfan patients > 26 years we compared health outcomes, costs and clinical factors. Comparisons were made between CV and pulmonary-related hospital discharges and those not primarily associated with CV or pulmonary manifestations. Methods: We used data from the 2012 Nationwide Inpatient Sample (NIS) to complete the study. Marfan Syndrome patients > 26 years were identified using ICD-9 code 759.82. Patients were stratified by primary diagnosis; CV (CCS:096,097,100,101,103-113,115-118) or pulmonary-related (CCS:128-131,133,134) conditions. Descriptive and inferential statistics were used to compare demographics [race, Charlson Comorbidity Index (CCI), region, and payer information] and healthcare outcomes and charges [length of stay (LOS), mortality, and total charges]. Chi-square and t-tests were used for statistical analysis. The reference group for all analyses included hospital discharges that were not CV or pulmonary-related. Results: 954 Marfan syndrome patients were identified, of which 284 (29.7%) were CV, 38 (3.9%) pulmonary, and 632 (66.2%) for the reference group. Mean CCI scores, LOS, and total charges among CV patients
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.